Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.
<h4>Background</h4>The response to cytotoxic chemotherapy varies greatly in patients with advanced non-small cell lung cancer (NSCLC), and molecular markers may be useful in determining a preferable therapeutic approach for individual patients. This retrospective study was performed to e...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24647522/?tool=EBI |
_version_ | 1818338038023979008 |
---|---|
author | Xiaopeng Dong Yingtao Hao Yucheng Wei Qiuwei Yin Jiajun Du Xiaogang Zhao |
author_facet | Xiaopeng Dong Yingtao Hao Yucheng Wei Qiuwei Yin Jiajun Du Xiaogang Zhao |
author_sort | Xiaopeng Dong |
collection | DOAJ |
description | <h4>Background</h4>The response to cytotoxic chemotherapy varies greatly in patients with advanced non-small cell lung cancer (NSCLC), and molecular markers may be useful in determining a preferable therapeutic approach for individual patients. This retrospective study was performed to evaluate the predictive value of ribonucleotide reductase regulatory subunit M1 (RRM1) on the therapeutic efficacy of platinum-based chemotherapy in patients with NSCLC.<h4>Methods</h4>Patients with advanced NSCLC who received platinum doublet chemotherapy (n = 229) were included in this retrospective study, and their clinical outcomes were analyzed according to RRM1 expression.<h4>Results</h4>In patients receiving gemcitabine-based therapy, the disease control rate (DCR) and progression-free survival (PFS) of patients with RRM1-negative tumors were significantly higher than in patients with RRMI-positive tumors (P = 0.041 and P = 0.01, respectively), and multivariate analysis showed that RRM1 expression was an independent prognostic factor (P = 0.013). No similar differences were found in patients receiving docetaxel- or vinorelbine-based therapy. In RRM1-positive patients, the DCRs for docetaxel and vinorelbine were higher than for gemcitabine (P = 0.047 and P = 0.047, respectively), and docetaxel and vinorelbine showed a longer PFS than gemcitabine-based chemotherapy (P = 0.012 and P = 0.007). No similar differences were found among patients with RRM1-negative tumors.<h4>Conclusions</h4>Negative RRM1 expression in advanced NSCLC is associated with a higher response rate to gemcitabine-based chemotherapy. In patients with RRM1-positive tumors, docetaxel and vinorelbine showed a higher therapeutic efficacy than gemcitabine-based therapy. Additional prospective studies are needed to investigate the predictive meaning of RRM1 in the response to chemotherapy. |
first_indexed | 2024-12-13T15:04:45Z |
format | Article |
id | doaj.art-5191222fd2fd4354ac4b64cd90488992 |
institution | Directory Open Access Journal |
issn | 1932-6203 |
language | English |
last_indexed | 2024-12-13T15:04:45Z |
publishDate | 2014-01-01 |
publisher | Public Library of Science (PLoS) |
record_format | Article |
series | PLoS ONE |
spelling | doaj.art-5191222fd2fd4354ac4b64cd904889922022-12-21T23:41:02ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0193e9232010.1371/journal.pone.0092320Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.Xiaopeng DongYingtao HaoYucheng WeiQiuwei YinJiajun DuXiaogang Zhao<h4>Background</h4>The response to cytotoxic chemotherapy varies greatly in patients with advanced non-small cell lung cancer (NSCLC), and molecular markers may be useful in determining a preferable therapeutic approach for individual patients. This retrospective study was performed to evaluate the predictive value of ribonucleotide reductase regulatory subunit M1 (RRM1) on the therapeutic efficacy of platinum-based chemotherapy in patients with NSCLC.<h4>Methods</h4>Patients with advanced NSCLC who received platinum doublet chemotherapy (n = 229) were included in this retrospective study, and their clinical outcomes were analyzed according to RRM1 expression.<h4>Results</h4>In patients receiving gemcitabine-based therapy, the disease control rate (DCR) and progression-free survival (PFS) of patients with RRM1-negative tumors were significantly higher than in patients with RRMI-positive tumors (P = 0.041 and P = 0.01, respectively), and multivariate analysis showed that RRM1 expression was an independent prognostic factor (P = 0.013). No similar differences were found in patients receiving docetaxel- or vinorelbine-based therapy. In RRM1-positive patients, the DCRs for docetaxel and vinorelbine were higher than for gemcitabine (P = 0.047 and P = 0.047, respectively), and docetaxel and vinorelbine showed a longer PFS than gemcitabine-based chemotherapy (P = 0.012 and P = 0.007). No similar differences were found among patients with RRM1-negative tumors.<h4>Conclusions</h4>Negative RRM1 expression in advanced NSCLC is associated with a higher response rate to gemcitabine-based chemotherapy. In patients with RRM1-positive tumors, docetaxel and vinorelbine showed a higher therapeutic efficacy than gemcitabine-based therapy. Additional prospective studies are needed to investigate the predictive meaning of RRM1 in the response to chemotherapy.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24647522/?tool=EBI |
spellingShingle | Xiaopeng Dong Yingtao Hao Yucheng Wei Qiuwei Yin Jiajun Du Xiaogang Zhao Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression. PLoS ONE |
title | Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression. |
title_full | Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression. |
title_fullStr | Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression. |
title_full_unstemmed | Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression. |
title_short | Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression. |
title_sort | response to first line chemotherapy in patients with non small cell lung cancer according to rrm1 expression |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24647522/?tool=EBI |
work_keys_str_mv | AT xiaopengdong responsetofirstlinechemotherapyinpatientswithnonsmallcelllungcanceraccordingtorrm1expression AT yingtaohao responsetofirstlinechemotherapyinpatientswithnonsmallcelllungcanceraccordingtorrm1expression AT yuchengwei responsetofirstlinechemotherapyinpatientswithnonsmallcelllungcanceraccordingtorrm1expression AT qiuweiyin responsetofirstlinechemotherapyinpatientswithnonsmallcelllungcanceraccordingtorrm1expression AT jiajundu responsetofirstlinechemotherapyinpatientswithnonsmallcelllungcanceraccordingtorrm1expression AT xiaogangzhao responsetofirstlinechemotherapyinpatientswithnonsmallcelllungcanceraccordingtorrm1expression |